Linda Mol
Netherlands Comprehensive Cancer Organisation(NL)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Cancer Treatment and Pharmacology, Genetic factors in colorectal cancer, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer(2009)1,350 cited
- → Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial(2007)629 cited
- → Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial(2019)316 cited
- → A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity(2008)213 cited
- → Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases(2010)164 cited
- → Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature(2011)161 cited
- → Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)(2008)130 cited
- → Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy(2011)95 cited
- → The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)(2014)88 cited
- → Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group(2017)83 cited